ICPT - PDUFA date on 22/06/2023This is not a financial advice!
Upcoming catalysts on 18/5/2023 and 22/06/2023
We can accumulate here in the 13 zone, we could drop even furhter to support to the 11 zone.
I assume that wie are seeing a pre run up into the events. One strategy could be only playing that and sell before the news.
−24.39MXN
−2.88 BMXN
5.57 BMXN
About INTERCEPT PHARMACEUTICALS INC
Sector
CEO
Jerome B. Durso
Headquarters
Morristown
Website
Employees (FY)
341
Founded
2002
ISIN
US45845P1084
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.
ICPT Short$ICPT trading in supply with a head and shoulders pattern. The right shoulder has been consolidating for a while, so the h&S may be rather weak. Also watching for a breakout to the upside if supply is breached.
Alternate Bat/BearishShort interest is a bit over 45% depending on where you look.
Some would calculate targets at these levels.
Bearish Harami right now that can change by close.
When short is this high, sometimes it can cause a squeeze. Not a frequent occurrence but it does happen.
No recommendation.
A short squ
Intercept Announces Positive Data in Fibrosis due to NASHICPT: Intercept Pharmaceuticals, Inc.
2022-07-07 07:30:00
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
ICPTThis is not a trade advice, this is my personal opinion and it may be wrong.
Constructive criticism is welcomed!
ICPT has triple confirmed a bottom. There are two high gaps it needs to fill. These gaps are on the daily, and,... do not get filed over night (which comes from OTC moves/"bets"). By mathematical law you cannot add a level or volume without it being on the permanent record (LEDGER)... There is 1 perfect ledger that will fix all of thi
Intercept Pharmaceuticals Announces Convertible Notes Exchange, ICPT: Intercept Pharmaceuticals, Inc.
2021-08-10 21:43:33
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
ICPT - Long Setup Big recent purchase from Director in March. $5m+ at 21.17 and 56% increase. Break above 22.57, Stop signal 19.21. Target 1 27.78., Target 2 Momentum. September $25 call options are $2.25
ICPT - Long Setup Short squeeze candidate. 21.5% short float. Watch for a break of 22.09. Stop signal 20.43. First target 24.43. Second target 25.87.
ICPT LongTry to buy historical low
Downtrend Wedge near breakout
RSI Divergence
WR>-80 (my scripts: Williams %R two lines)
Entry 18
Stop 15
Target 28
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ICPT is 329.00 MXN — it has decreased by 30.74% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange INTERCEPT PHARMACEUTICALS INC stocks are traded under the ticker ICPT.
INTERCEPT PHARMACEUTICALS INC is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ICPT stock is 44.38% volatile and has beta coefficient of −0.69. Check out the list of the most volatile stocks — is INTERCEPT PHARMACEUTICALS INC there?
ICPT earnings for the last quarter are −2.40 MXN per share, whereas the estimation was −8.71 MXN resulting in a 72.46% surprise. The estimated earnings for the next quarter are −4.38 MXN per share. See more details about INTERCEPT PHARMACEUTICALS INC earnings.
INTERCEPT PHARMACEUTICALS INC revenue for the last quarter amounts to 1.44 B MXN despite the estimated figure of 1.36 B MXN. In the next quarter revenue is expected to reach 1.54 B MXN.
Yes, you can track INTERCEPT PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
ICPT net income for the last quarter is −48.11 M MXN, while the quarter before that showed −99.86 M MXN of net income which accounts for 51.83% change. Track more INTERCEPT PHARMACEUTICALS INC financial stats to get the full picture.
No, ICPT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ICPT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTERCEPT PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 341.00 employees. See our rating of the largest employees — is INTERCEPT PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INTERCEPT PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INTERCEPT PHARMACEUTICALS INC stock shows the strong sell signal. See more of INTERCEPT PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTERCEPT PHARMACEUTICALS INC EBITDA is −955.31 M MXN, and current EBITDA margin is −23.09%. See more stats in INTERCEPT PHARMACEUTICALS INC financial statements.